Metreleptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Metreleptin
- Metreleptin: From Original Indication (Not Available) to Familial Generalized Lentiginosis
Metreleptin: From Original Indication (Not Available) to Familial Generalized Lentiginosis
One-Sentence Summary
Metreleptin’s original approved indication is not recorded in this evidence pack, and no market authorization currently exists in Taiwan. The TxGNN model predicts a possible link to Familial Generalized Lentiginosis, but this is supported by 0 clinical trials and 0 publications — the prediction rests entirely on knowledge-graph topology, not biological or clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — evidence pack contains no recorded original indication and no license records |
| Predicted New Indication | Familial Generalized Lentiginosis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| EU/TW Market Status | Not Marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the structured record (flagged as a High-severity data gap, DG002). Based on the repurposing rationale accompanying this prediction, Metreleptin is a leptin analog that primarily acts on hypothalamic leptin receptors to regulate energy metabolism and fat distribution — this is the only mechanistic anchor available for this drug.
There is no known or reported biological relationship between the leptin signaling pathway and familial generalized lentiginosis, a pigmentary skin disorder. The rationale note explicitly states that the TxGNN model’s high score reflects knowledge-graph topological similarity rather than any established mechanistic or clinical connection. The same caveat applies to the remaining nine predicted indications in this pack (including two unrelated syndromes, two rare pigmentary/genetic disorders, and three unrelated malignancies), none of which have a plausible link to leptin biology based on currently available information.
Because the original indication itself is not recorded in this evidence pack, no comparison between the original and predicted indications can be made at this time. This further limits confidence in the biological plausibility of the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU/Taiwan Market Information
No marketing authorization records are available. Metreleptin is currently not marketed in this jurisdiction (0 licenses on file).
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug-drug interaction data are all currently missing from this evidence pack — TFDA label/warning data is flagged as a Blocking-severity gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by TxGNN topological score (L5, no clinical trials, no literature), the original indication and mechanism of action are both undocumented in this pack, and a Blocking-severity safety data gap (missing TFDA label/warnings) prevents any preliminary safety assessment (S1). There is no basis to proceed further at this time.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (Blocking gap, DG001) — required before any S1 safety screening
- Confirmed mechanism of action from DrugBank or primary literature (High-priority gap, DG002)
- The drug’s actual original indication(s), currently missing from the evidence pack
- Any preclinical or case-level evidence connecting leptin signaling to the predicted indication, before this candidate can be re-scored above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.